NEJM: Prevention of 1/3 of major cardiovascular events Autumn daffodils to treat chronic coronary heart disease added evidence.
AP-T: Patients with chronic hepatitis B with low ALT levels are very unlikely to develop significant liver inflammation.
World J Gastroenterology: Nutritional status and nutritional support for the role of chronic
GSK oligonucleotide therapy has been approved clinically or "functionally cured" chronic hepatitis B for the first time in China.
Gastroenterology: Predictor of chronic fatigue in adolescents six months after acute EB virus infection.
EU approves Epclusa for chronic hepatitis C in children!
Fat crystals cause chronic inflammation.
"Functional cure" chronic hepatitis B dawned, Yang Sen, GSK, Vir, etc. announced the latest clinical results.
"Functional cure" chronic hepatitis B dawn Yang Sen, GSK, etc. announced the latest clinical results.
Reducing the risk of death in patients with chronic kidney disease by 31% AstraZeneed has been a net breakthrough.
JCI: How chronic stress leads to bone loss.
Chronic nasal-sinusitis with new drugs for nasal psychics (CRSwNP)! AstraZeneta Fasenra (Benali Pearl Monomass) Phase 3 clinical success!
Acta Neuropathologica: Tau deposition characteristics in chronic traumatic encephalopathy (CTE): Application of McKee-CTE phased solutions.
JNNP: The frequency of diabetes and other complications in chronic inflammatory demyelinative
and innovation results to help the prevention and treatment of primary-level chronic diseases.
Clin?? . . Trans? Analysis of differences in detobation desire between patients with and without chronic constipation.
Diabetologia: Sex-specific association of insulin resistance with chronic kidney disease and kidney function: a two-way Mendel randomized study.
The FDA has granted Bcl-2 inhibitor APG-2575 orphan drug eligibility for the treatment of chronic lymphocytic leukemia.
Yassin Pharmaceutical Bcl-2 inhibitors were again qualified by the FDA orphan drug to treat chronic lymphocytic leukemia.
Aceh Pharmaceutical Bcl-2 inhibitor APG-2575 has been approved by the FDA orphan drug for the treatment of chronic lymphocytic leukemia.